Evidence map›Paper›PMID 36062197›Full record

ArticleOxidative medicine and cellular longevity2022

Network Pharmacology, Molecular Docking, and Experimental Validation to Unveil the Molecular Targets and Mechanisms of Compound Fuling Granule to Treat Ovarian Cancer.

Zhaoyi Li, Qingling Liu, Ying Zhu, Lichao Wu, Wenhong Liu, Junfeng Li, Zhiqian Zhang, Fangfang Tao

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhaoyi LiDepartment of Dermatology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID https://orcid.org/0000-0003-1852-7241
Qingling LiuDepartment of Immunology and Microbiology, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID https://orcid.org/0000-0002-2713-2359
Ying ZhuDepartment of Medical Oncology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID https://orcid.org/0000-0002-5502-3571
Lichao WuDepartment of Immunology and Microbiology, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID https://orcid.org/0000-0002-7280-2761
Wenhong LiuDepartment of Immunology and Microbiology, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID https://orcid.org/0000-0002-9202-0687
Junfeng LiDepartment of Immunology and Microbiology, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID https://orcid.org/0000-0002-5164-3933
Zhiqian ZhangState Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China.ORCID https://orcid.org/0000-0003-1226-4807
Fangfang TaoDepartment of Immunology and Microbiology, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID https://orcid.org/0000-0002-2090-2701
Zhejiang Chinese Medical University · CNNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Compound fuling granule (CFG) is a traditional Chinese medicine formula that is used for more than twenty years to treat ovarian cancer (OC) in China. However, the underlying processes have yet to be completely understood. This research is aimed at uncovering its molecular mechanism and identifying possible therapeutic targets. Methods: Significant genes were collected from Therapeutic Target Database and Database of Gene-Disease Associations. The components of CFG were analyzed by LC-MS/MS, and the active components of CFG were screened according to their oral bioavailability and drug-likeness index. The validated targets were extracted from PharmMapper and PubChem databases. Venn diagram and STRING website diagrams were used to identify intersection targets, and a protein-protein interaction network was prepared using STRING. The ingredient-target network was established using Cytoscape. Molecular docking was performed to visualize the molecule-protein interactions using PyMOL 2.3. Enrichment and pathway analyses were performed using FunRich software and Reactome pathway, respectively. Experimental validations, including CCK-8 assay, wound-scratch assay, flow cytometry, western blot assay, histopathological examination, and immunohistochemistry, were conducted to verify the effects of CFG on OC cells. Results: A total of 56 bioactive ingredients of CFG and 185 CFG-OC-related targets were screened by network pharmacology analysis. The potential therapeutic targets included moesin, glutathione S-transferase kappa 1, ribonuclease III (DICER1), mucin1 (MUC1), cyclin-dependent kinase 2 (CDK2), E1A binding protein p300, and transcription activator BRG1. Reactome analysis showed 51 signaling pathways ( Conclusion: Based on network pharmacology, molecular docking, and experimental validation, the potential mechanism underlying the function of CFG in OC was explored, which supplies the theoretical groundwork for additional pharmacological investigation.

Indexed as

Drugs, Chinese HerbalOvarian NeoplasmsWolfiporiaCarcinoma, Ovarian EpithelialChromatography, LiquidDEAD-box RNA HelicasesFemaleHumansMolecular Docking SimulationNetwork PharmacologyRibonuclease IIITandem Mass SpectrometryDEAD-box RNA HelicasesDICER1 protein, humanDrugs, Chinese HerbalRibonuclease III

Identifiers

PMID36062197
PMCPMC9428684
OpenAlexW4292814314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.